A Phase 3 interventional study of RSVPreF3 OA investigational vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Active, not recruiting at 46 sites in 5 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 4th largest by enrollment, is one of 4 that started in 2021, is one of 15 in phase 3, and was the 1st registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 4 started in 2021.
This study's enrollment of 1,720 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 976 across the 17 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline: 1 open now, 5 under way, 3 of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 7th largest by enrollment, is one of 6 that started in 2021, is one of 21 in phase 3, and was the 17th registered.
GlaxoSmithKline’s Respiratory Syncytial Virus Infections studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, from their registry updates:
Among GlaxoSmithKline’s 40 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, reactogenicity, immunogenicity and long-term persistence of immune response up to 5 years following a single dose vaccination of GSK's investigational vaccine RSVPreF3 OA, in adults aged 60 years and above. The study will also evaluate the immunogenicity, safety and reactogenicity of additional vaccine doses given according to different revaccination schedules.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical conditions
Prior/Concomitant therapy
Prior/Concurrent clinical study experience
Other exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and 2 revaccination doses at 12 months post-Dose 1 and at 24 months post-Dose 1, respectively and are followed up until Month 60.
Biological: RSVPreF3 OA investigational vaccine
Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and 2 revaccination doses at 24 months post-Dose 1 and at 48 months post-Dose 1, respectively and are followed up until Month 60.
Biological: RSVPreF3 OA investigational vaccine
Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and are followed up until Month 36. At Month 36, participants in this group will be re-randomized in 2 groups: RSV\_1dose\_M36 (which will receive 1 additional revaccination dose at Month 36 and will be followed up until Month 60) and RSV\_1dose\_Flexible (which will receive 1 additional revaccination dose at Month 60, and will be followed up until study end at Month 72).
Biological: RSVPreF3 OA investigational vaccine
RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
Humoral Immune Response in Terms of Respiratory Syncytial Virus (RSV)-A Neutralizing Antibody Geometric Mean Titers (GMTs) at Day 1
RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Time frame: At Day 1
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Day 31
RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.
Time frame: At Day 31
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 6
RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.
Time frame: At Month 6
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 12
RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.
Time frame: At Month 12
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 1
RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.
Time frame: At Day 1
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 31
RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.
Time frame: At Day 31
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 6
RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.
Time frame: At Month 6
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 12
RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.
Time frame: At Month 12
Humoral Immune Response in Terms of RSVPreF3 Immunoglobulin G (IgG) Antibody Geometric Mean Concentrations (GMCs) at Day 1
Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by enzyme-linked immunosorbent assay (ELISA). The corresponding antibody GMC was expressed in Elisa Laboratory Units/milliliter (ELU/mL).
Time frame: At Day 1
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Day 31
Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
Time frame: At Day 31
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 6
Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
Time frame: At Month 6
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 12
Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
Time frame: At Month 12
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 18
Month 18 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Time frame: At Month 18
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 24
Month 24 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Time frame: At Month 24
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 30
Month 30 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Time frame: At Month 30
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 36
Month 36 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Time frame: At Month 36
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 13
Month 13 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Time frame: At Month 13
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 25
Month 25 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Time frame: At Month 25
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 18
Month 18 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Time frame: At Month 18
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 24
Month 24 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Time frame: At Month 24
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 30
Month 30 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Time frame: At Month 30
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 36
Month 36 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Time frame: At Month 36
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 13
Month 13 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Time frame: At Month 13
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 25
Month 25 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Time frame: At Month 25
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 18
Month 18 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
Time frame: At Month 18
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 24
Month 24 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
Time frame: At Month 24
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 30
Month 30 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
Time frame: At Month 30
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 36
Month 36 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
Time frame: At Month 36
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 13
Month 13 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
Time frame: At Month 13
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 25
Month 25 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
Time frame: At Month 25
Cell-Mediated Immunity (CMI) Response in Terms of Frequency of RSVPreF3-specific Cluster of Differentiation CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1
Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Day 1
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1
Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Day 1
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31
Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Day 31
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31
Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Day 31
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6
Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Month 6
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6
Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Month 6
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12
Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Month 12
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12
Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Month 12
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 18
Month 18 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Month 18
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 18
Month 18 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Month 18
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 24
Month 24 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Month 24
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 24
Month 24 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Month 24
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 30
Month 30 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Month 30
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 30
Month 30 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Month 30
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 36
Month 36 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Month 36
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 36
Month 36 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Month 36
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 13
Month 13 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Month 13
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 13
Month 13 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Month 13
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 25
Month 25 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Month 25
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 25
Month 25 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At Month 25
Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Day 1
The solicited administration-site events were erythema, pain and swelling at the injection site.
Time frame: During the 4-day follow up period after first vaccination (vaccine administered on Day 1)
Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Month 12
Month 12 to Month 18 data will be disclosed during final posting. The solicited administration-site events were erythema, pain and swelling at the injection site.
Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Month 24
Month 24 data will be disclosed during final posting. The solicited administration-site events were erythema, pain and swelling at the injection site.
Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Day 1
The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0 degree Celsius \[°C\]), headache and myalgia.
Time frame: During the 4-day follow up period after vaccination (vaccine administered on Day 1)
Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Month 12
Month 12 to Month 18 data will be disclosed during final posting. The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0°C), headache and myalgia.
Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Month 24
Month 24 data will be disclosed during final posting. The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0 degree Celsius (°C)), headache and myalgia.
Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Number of Participants With Any Unsolicited Adverse Events (AEs) Following Vaccination at Day 1
An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: During the 30-day follow up period after vaccination (vaccine administered on Day 1)
Number of Participants With Any Unsolicited AEs Following Vaccination at Month 12
Month 12 to Month 18 data will be disclosed during final posting. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Number of Participants With Any Unsolicited AEs Following Vaccination at Month 24
Month 24 data will be disclosed during final posting. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Number of Participants With Serious Adverse Events (SAE) Following Vaccination at Day 1
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.
Time frame: From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)
Number of Participants With SAEs Following Vaccination at Month 12
Month 12 to Month 18 data will be disclosed during final posting. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.
Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Number of Participants With SAEs Following Vaccination at Month 24
Month 24 data will be disclosed during final posting. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.
Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Number of Participants Reporting Any Potential Immune-mediated Disease (pIMD) Following Vaccination at Day 1
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)
Number of Participants Reporting Any pIMD Following Vaccination at Month 12
Month 12 to Month 18 data will be disclosed during final posting. pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Number of Participants Reporting Any pIMD Following Vaccination at Month 24
Month 24 data will be disclosed during final posting. pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Number of Participants With a Fatal SAE, Related SAE and Related pIMDs
A fatal SAE is any untoward medical occurrence that results in death. A related SAE is an SAE considered to be causally related to the study intervention. A related pIMD is a pIMD considered to be causally related to the study intervention. The study is ongoing at the time of the results posting. Results for Months 18 up to study end (Month 36) will be updated during final posting.
Time frame: From first vaccination (Day 1) up to study end (Month 36)
The demography, immunogenicity, reactogenicity and safety data currently presented is reported only for the first 12 months of the study timeline. The follow-up data (up to 36 months) will be updated during final posting.
| Milestone | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Started | 993 | 329 | 331 |
| Completed | 938 | 317 | 317 |
| Not completed | 55 | 12 | 14 |
| Withdrew: Adverse event (ae) requiring expedited reporting | 9 | 1 | 3 |
| Withdrew: Lost to follow-up | 7 | 4 | 3 |
| Withdrew: Consent withdrawal, not due to a serious adverse event (sae) | 26 | 7 | 6 |
| Withdrew: Migrated / moved from the study area | 5 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 1 |
| Withdrew: Ongoing | 6 | 0 | 1 |
| Withdrew: Unsolicited non-serious adverse event | 1 | 0 | 0 |
RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
| Titers (ED60) | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Humoral Immune Response in Terms of Respiratory Syncytial Virus (RSV)-A Neutralizing Antibody Geometric Mean Titers (GMTs) at Day 1 | 832.4 (763.4 to 907.7) | 864.9 (790.6 to 946.1) | 896.8 (815.9 to 985.8) |
RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.
| Titers (ED60) | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Day 31 | 8827.2 (7905 to 9857) | 8906.6 (7972.3 to 9950.3) | 9585.6 (8448.8 to 10875.5) |
RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.
| Titers (ED60) | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 6 | 3465.2 (3140.9 to 3823) | 3600.1 (3242.2 to 3997.5) | 4223.1 (3795.3 to 4699) |
RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.
| Titers (ED60) | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 12 | 2529.9 (2274.5 to 2814) | 2695.7 (2421.4 to 3001) | 2800.1 (2501.6 to 3134.3) |
RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.
| Titers (ED60) | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 1 | 1138.7 (1046.2 to 1239.3) | 1325.9 (1206.9 to 1456.6) | 1258.7 (1142 to 1387.4) |
RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.
| Titers (ED60) | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 31 | 9219.7 (8368.7 to 10157.3) | 9955.2 (9002.1 to 11009.3) | 9756.1 (8785.4 to 10834) |
RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.
| Titers (ED60) | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 6 | 3886.4 (3563.5 to 4238.6) | 4484.6 (4063.8 to 4949) | 4570.6 (4152 to 5031.4) |
RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.
| Titers (ED60) | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 12 | 2671.4 (2433.3 to 2932.9) | 3015.4 (2737.9 to 3321) | 2977.1 (2669.6 to 3320) |
Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by enzyme-linked immunosorbent assay (ELISA). The corresponding antibody GMC was expressed in Elisa Laboratory Units/milliliter (ELU/mL).
| ELU/mL | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Humoral Immune Response in Terms of RSVPreF3 Immunoglobulin G (IgG) Antibody Geometric Mean Concentrations (GMCs) at Day 1 | 7334.7 (6868.3 to 7832.8) | 7437.1 (6948.6 to 7959.9) | 7759 (7212.5 to 8346.8) |
Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
| ELU/mL | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Day 31 | 86929.7 (80662.7 to 93683.6) | 92664.7 (86050.1 to 99787.8) | 94249.4 (87660.7 to 101333.3) |
Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
| ELU/mL | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 6 | 33855.9 (31405.3 to 36497.7) | 35193.5 (32623.6 to 37965.9) | 36525.7 (33938 to 39310.7) |
Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
| ELU/mL | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 12 | 24733.5 (22994.3 to 26604.2) | 26484.1 (24651.7 to 28452.8) | 27360.3 (25476.7 to 29383) |
Month 18 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Results for this outcome have not been posted.
Month 24 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Results for this outcome have not been posted.
Month 30 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Results for this outcome have not been posted.
Month 36 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Results for this outcome have not been posted.
Month 13 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Results for this outcome have not been posted.
Month 25 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Results for this outcome have not been posted.
Month 18 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Results for this outcome have not been posted.
Month 24 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Results for this outcome have not been posted.
Month 30 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Results for this outcome have not been posted.
Month 36 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Results for this outcome have not been posted.
Month 13 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Results for this outcome have not been posted.
Month 25 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).
Results for this outcome have not been posted.
Month 18 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
Results for this outcome have not been posted.
Month 24 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
Results for this outcome have not been posted.
Month 30 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
Results for this outcome have not been posted.
Month 36 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
Results for this outcome have not been posted.
Month 13 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
Results for this outcome have not been posted.
Month 25 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.
Results for this outcome have not been posted.
Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
| CD4 atl2_7m/ million of CD4+ cells | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Cell-Mediated Immunity (CMI) Response in Terms of Frequency of RSVPreF3-specific Cluster of Differentiation CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1 | 202 (83 to 376) | 143 (26 to 294) | 171 (65 to 385) |
Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
| CD8 atl2_7m/ million of CD8+ cells | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1 | 33 (1 to 110) | 32 (1 to 103) | 2 (1 to 107) |
Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
| CD4 atl2_7m/ million of CD4+ cells | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31 | 1310 (813 to 2155) | 1292.5 (820.5 to 2254) | 1570 (876 to 1971) |
Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
| CD8 atl2_7m/ million of CD8+ cells | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31 | 26 (1 to 129) | 58 (1 to 143) | 5 (1 to 101) |
Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
| CD4 atl2_7m/ million of CD4+ cells | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6 | 662 (428 to 1026) | 644 (442 to 1100) | 695 (427 to 1131) |
Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
| CD8 atl2_7m/ million of CD8+ cells | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6 | 38 (1 to 113) | 24.5 (1 to 103.5) | 26 (1 to 87) |
Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
| CD4 atl2_7m/ million of CD4+ cells | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12 | 564 (348 to 898) | 525 (345 to 818) | 671 (374.5 to 1072.5) |
Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
| CD8 atl2_7m/ million of CD8+ cells | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12 | 1 (1 to 81) | 18 (1 to 108) | 22 (1 to 104) |
Month 18 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Results for this outcome have not been posted.
Month 18 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Results for this outcome have not been posted.
Month 24 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Results for this outcome have not been posted.
Month 24 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Results for this outcome have not been posted.
Month 30 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Results for this outcome have not been posted.
Month 30 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Results for this outcome have not been posted.
Month 36 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Results for this outcome have not been posted.
Month 36 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Results for this outcome have not been posted.
Month 13 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Results for this outcome have not been posted.
Month 13 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Results for this outcome have not been posted.
Month 25 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Results for this outcome have not been posted.
Month 25 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Results for this outcome have not been posted.
The solicited administration-site events were erythema, pain and swelling at the injection site.
| Participants | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Erythema | 99 | 38 | 22 |
| Pain | 595 | 201 | 200 |
| Swelling | 75 | 33 | 16 |
Month 12 to Month 18 data will be disclosed during final posting. The solicited administration-site events were erythema, pain and swelling at the injection site.
Results for this outcome have not been posted.
Month 24 data will be disclosed during final posting. The solicited administration-site events were erythema, pain and swelling at the injection site.
Results for this outcome have not been posted.
The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0 degree Celsius \[°C\]), headache and myalgia.
| Participants | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Arthralgia | 157 | 49 | 49 |
| Fatigue | 307 | 100 | 110 |
| Fever | 13 | 5 | 7 |
| Headache | 187 | 70 | 79 |
| Myalgia | 336 | 107 | 109 |
Month 12 to Month 18 data will be disclosed during final posting. The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0°C), headache and myalgia.
Results for this outcome have not been posted.
Month 24 data will be disclosed during final posting. The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0 degree Celsius (°C)), headache and myalgia.
Results for this outcome have not been posted.
An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Participants | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Number of Participants With Any Unsolicited Adverse Events (AEs) Following Vaccination at Day 1 | 125 | 45 | 55 |
Month 12 to Month 18 data will be disclosed during final posting. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Results for this outcome have not been posted.
Month 24 data will be disclosed during final posting. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Results for this outcome have not been posted.
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.
| Participants | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAE) Following Vaccination at Day 1 | 36 | 16 | 15 |
Month 12 to Month 18 data will be disclosed during final posting. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.
Results for this outcome have not been posted.
Month 24 data will be disclosed during final posting. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.
Results for this outcome have not been posted.
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
| Participants | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Number of Participants Reporting Any Potential Immune-mediated Disease (pIMD) Following Vaccination at Day 1 | 0 | 1 | 0 |
Month 12 to Month 18 data will be disclosed during final posting. pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Results for this outcome have not been posted.
Month 24 data will be disclosed during final posting. pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Results for this outcome have not been posted.
A fatal SAE is any untoward medical occurrence that results in death. A related SAE is an SAE considered to be causally related to the study intervention. A related pIMD is a pIMD considered to be causally related to the study intervention. The study is ongoing at the time of the results posting. Results for Months 18 up to study end (Month 36) will be updated during final posting.
Results for this outcome have not been posted.
Collected over Serious Adverse Events (SAEs) were collected from Day 1 to Month 12. Non-serious adverse (Other Adverse events) events were collected within 30 days following first vaccination (vaccine administered at Day 1). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RSV_annual | 3/993 (0.3%) | 46/993 (4.6%) | 744/993 (74.9%) |
| RSV_flexible Revaccination | 1/329 (0.3%) | 16/329 (4.9%) | 251/329 (76.3%) |
| RSV_1dose | 3/331 (0.9%) | 19/331 (5.7%) | 253/331 (76.4%) |
| Event | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| DeathGeneral disorders | 7/993 | 4/329 | 5/331 |
| Atrial fibrillationCardiac disorders | 2/993 | 2/329 | 2/331 |
| Coronary artery diseaseCardiac disorders | 3/993 | 1/329 | 0/331 |
| Myocardial infarctionCardiac disorders | 1/993 | 1/329 | 0/331 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/993 | 1/329 | 1/331 |
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/993 | 1/329 | 0/331 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/993 | 1/329 | 0/331 |
| CellulitisInfections and infestations | 1/993 | 1/329 | 0/331 |
| Urinary tract infectionInfections and infestations | 1/993 | 1/329 | 0/331 |
| Post procedural infectionInfections and infestations | 0/993 | 1/329 | 0/331 |
| Event | RSV_annual | RSV_flexible Revaccination | RSV_1dose |
|---|---|---|---|
| Injection site painGeneral disorders | 595/993 | 201/329 | 200/331 |
| MyalgiaMusculoskeletal and connective tissue disorders | 337/993 | 108/329 | 110/331 |
| FatigueGeneral disorders | 307/993 | 101/329 | 110/331 |
| HeadacheNervous system disorders | 192/993 | 72/329 | 81/331 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 162/993 | 50/329 | 50/331 |
| Injection site erythemaGeneral disorders | 99/993 | 38/329 | 23/331 |
| Injection site swellingGeneral disorders | 77/993 | 33/329 | 17/331 |
| PyrexiaGeneral disorders | 14/993 | 6/329 | 8/331 |
| Herpes zosterInfections and infestations | 3/993 | 0/329 | 4/331 |
| ChillsGeneral disorders | 6/993 | 3/329 | 0/331 |
| Age, Continuous(YEARS) | RSV_annual | RSV_flexible Revaccination | RSV_1dose | Total |
|---|---|---|---|---|
| Mean | 70.1 ± 6.6 | 69.9 ± 6.7 | 69.9 ± 6.7 | 70.0 ± 6.6 |
| Sex: Female, Male(Participants) | RSV_annual | RSV_flexible Revaccination | RSV_1dose | Total |
|---|---|---|---|---|
| Female | 542 | 182 | 180 | 904 |
| Male | 451 | 147 | 151 | 749 |
| Race/Ethnicity, Customized(Participants) | RSV_annual | RSV_flexible Revaccination | RSV_1dose | Total |
|---|---|---|---|---|
| American Indian Or Alaska Native | 2 | 0 | 0 | 2 |
| Asian | 296 | 102 | 98 | 496 |
| Black Or African American | 19 | 8 | 6 | 33 |
| Other - Unspecified | 0 | 0 | 1 | 1 |
| White | 676 | 219 | 226 | 1121 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Ran from Feb 2021 to primary completion in Jun 2022, 15 months.
Results were first posted in Dec 2023, 1 year 6 months after primary completion. A results delay was requested in Jun 2023.
Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 15 months is above that.
Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arexvy
Respiratory Syncytial Virus Infections →